What Is Drugs Made In America Acquisiti (DMII) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Drugs Made In America Acquisiti's intrinsic value is estimated at $2.59, suggesting the stock is overvalued at its current price of $10.09. With 9 out of 9 models flagging downside (-74.3% average return), the market may be pricing in unsustainable growth. The most optimistic model, ML-RIV, places fair value at $3.81 (-62.2%), while RCMH-DCF — the most conservative — estimates $0.48 (-95.2%). This +33.0% gap reflects genuine analytical uncertainty about Drugs Made In America Acquisiti's intrinsic worth.
What Do the Models Say About DMII?
9 of 13 models are currently active for DMII. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates DMII's intrinsic value at $2.66, implying -73.6% downside from the current price. See which stocks rank higher →
How Does DMII Rank in Blank Checks?
Among 204 Blank Checks stocks, DMII ranks #110 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.
See all Most Undervalued Blank Checks Stocks →
Drugs Made In America Acquisiti operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is DMII a Value Trap?
The Value Trap algorithm is not active for DMII. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Drugs Made In America Acquisiti. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Drugs Made In America Acquisiti is rated at 4.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +33.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every DMII valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across DMII's 9 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad